Skip to main content
VREOF logo

VREOF · Vireo Growth Inc. · Financials

Track VREOF — free
$9.01 +0.01 (+0.11%) At close · Oct 19
Market Cap
$431.07M
Shares
48.06M
Volume · Oct 19 12.7K Avg daily vol (3M) 45.84K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$268.77M +170.4%
FY2025 Revenue FY2020–FY2025
Net Income
-$68.11M -143.2%
FY2025 Net Income FY2020–FY2025
Gross Margin
47.29% -3.8pp
FY2025 Gross Margin FY2020–FY2025
Operating Margin
-0.39% -14pp
FY2025 Operating Margin FY2020–FY2025
Diluted EPS
-$2.70 +43.8%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
$3.71M +136.3%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$511.67M $268.77M $99.38M $88.13M $74.63MG $54.45M $49.21M
$39.32M — — — $39.42M $32.01M $31.11M
$248.9M $127.1M $50.77M $44.1M $30.91M $19.8M $17.13M
— 47.29% 51.09% 50.04% 41.42% 36.36% 34.8%
$163.79M $81.19M $28.06M $28.22M $33.82M $33.66M $26.37M
$11.95M $5.75M $720.13K $678.86K $676.57K $817.22K $615.09K
$24.11M $16.11M $2.54M $2.87M $3.34M $3.03M $2.48M
$247.24M $128.14M $37.21M $33.52M $37.85M $40.28M $40.17M
$1.65M -$1.05M $13.56M $10.58M -$6.94M -$20.48M -$23.04M
— -0.39% 13.65% 12% -9.3% -37.62% -46.82%
$25.76M $15.06M $16.1M $13.45M -$3.6M -$17.45M -$20.56M
$29.74M — $31.19M $31.26M $22.59M $10.58M $5.1M
-$16.66M -$38.86M -$30.46M -$28.4M -$29.63M -$9.09M $8.89M
-$15.01M -$39.91M -$16.89M -$17.82M -$36.56M -$29.57M -$14.15M
— $28.23M $11.11M $7.72M $5.89M $4.12M $8.79M
-$67.11M -$68.11M -$28.01M -$25.55M -$42.46M -$33.69M -$22.94M
— -25.34% -28.18% -28.99% -56.89% -61.88% -46.62%
USD/shares -$1.90 -$2.70 -$4.80 -$5.70 -$9.90 -$8.10 -$7.20
USD/shares -$1.90 -$2.70 -$4.80 -$5.70 -$9.90 -$8.10 -$7.20
shares — 24.49M 6.01M 4.51M 4.27M 4.13M 3.25M
shares — 24.49M 6.01M 4.51M 4.27M 4.13M 3.25M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-06-30 USD 13,400,000 10-Q filed 2026-08-14
Current portion of convertible debt 2026-06-30 USD 1,300,000 10-Q filed 2026-08-14
Current portion of secured debt 2026-06-30 USD 41,600,000 10-Q filed 2026-08-14
Noncurrent convertible debt 2026-06-30 USD 22,300,000 10-Q filed 2026-08-14
Noncurrent finance lease liabilities 2026-06-30 USD 8,800,000 10-Q filed 2026-08-14
Noncurrent operating lease liabilities 2026-06-30 USD 141,200,000 10-Q filed 2026-08-14
Noncurrent secured debt 2026-06-30 USD 257,200,000 10-Q filed 2026-08-14
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 1.91×
EV/EBIT
—
Peer median 12.47×
P/E (TTM)
—
Peer median 14.64×

Peer medians compare against the 50 similar-size Drug Manufacturers - Specialty & Generic companies (of 101 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Retail $219,933,107 $79,534,555 $73,620,866 $62,123,357 $44,692,385 $37,236,301
Wholesale Product $48,836,161 $19,849,666 $14,512,297 — — —
Wholesale Product — — — $12,502,510 $9,753,783 $11,972,314
Product And Service Other — — — — — $2,714
Key facts CIK 1771706 CUSIP 92767B204 Visit website Investor relations